comprehensive
Previous article:
The cancer drug shortage isn’t new — and neither are the solutions
Next article: Testing for cancer recurrence creates a new limbo for patients
Next article: Testing for cancer recurrence creates a new limbo for patients
focus
leisure time
-
Eli Lilly to pay $200M for Beam’s stake in gene
2025-09-30 12:57 -
Feds fine Medicare Advantage plans for overcharging members
2025-09-30 12:46 -
The FDA weighs the risks of candy
2025-09-30 12:04 -
AstraZeneca challenges Medicare drug negotiation program
2025-09-30 11:12 -
Why Sanofi got shellacked over its spinoff
2025-09-30 10:51 -
Radiation, mainstay of cancer treatment, begins a fade
2025-09-30 10:47